Brokerages Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) PT at $16.29

Key Points

• COMPASS Pathways PLC has received a consensus rating of "Moderate Buy" from analysts, with six out of seven firms recommending to buy the stock.
• The average 1-year target price for COMPASS Pathways shares is $16.29, significantly higher than its recent trading price of $4.90.
• Despite missing quarterly earnings estimates with a reported EPS of (0.38), the company continues to develop its psilocybin therapy for mental health treatment.

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $16.2857.

Several equities analysts recently commented on the stock. HC Wainwright dropped their price target on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, August 4th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $12.00 price target on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Evercore ISI reaffirmed an "in-line" rating and set a $6.00 price target (down previously from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price target on shares of COMPASS Pathways in a research report on Friday, August 1st.

Institutional Investors Weigh In On COMPASS Pathways

Several institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC grew its stake in COMPASS Pathways by 47.7% during the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company's stock worth $11,704,000 after buying an additional 1,350,698 shares during the period. Vivo Capital LLC grew its stake in COMPASS Pathways by 109.1% during the first quarter. Vivo Capital LLC now owns 3,362,385 shares of the company's stock worth $9,616,000 after buying an additional 1,754,385 shares during the period. ARK Investment Management LLC grew its stake in COMPASS Pathways by 4.0% during the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company's stock worth $5,162,000 after buying an additional 68,601 shares during the period. GMT Capital Corp grew its stake in COMPASS Pathways by 15.1% during the first quarter. GMT Capital Corp now owns 1,781,718 shares of the company's stock worth $5,096,000 after buying an additional 233,918 shares during the period. Finally, Woodline Partners LP grew its stake in COMPASS Pathways by 279.9% during the first quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock worth $5,019,000 after buying an additional 1,292,927 shares during the period. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Trading Up 2.5%

Shares of NASDAQ:CMPS traded up $0.13 during trading on Friday, reaching $5.17. The stock had a trading volume of 1,640,525 shares, compared to its average volume of 1,801,283. The business has a fifty day moving average price of $4.54 and a 200-day moving average price of $3.95. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16. The stock has a market cap of $495.53 million, a P/E ratio of -2.80 and a beta of 2.17. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $7.09.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). As a group, analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.